Detail akcie Vaxart Rg online

Business Summary: Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Vaxart Inc revenues increased from $2.2M to $20.9M. Net loss decreased 36% to $15.6M. Revenues reflect Government Contract increase from $1.6M to $19.3M, Royalty Income - Business increase from $585K to $1.6M. Lower net loss reflects pharmaceutical segment loss decrease of 38% to $14.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.14 to -$0.07.